EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy

Shi-Jie Ye, Rui-da Huang, Xin Fei, Zhu-Lei Tao, Wei-Hua Liu, Qi Ma

Postgraduate Medical Journal · 2024

DOI: 10.1093/postmj/qgae063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Postgraduate Medical Journal, 2024. Verfasst von Shi-Jie Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Science Center, Ningbo University, Zhejiang, Ningbo 315211, China. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: hejiang Natural Science Fund, Ningbo Clinical Research Center for Urological Disease (No.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For metastatic prostate cancer, androgen deprivation therapy (ADT) is the key strategy to control the disease. However, after 18–24 months of treatment, most patients will progress from metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) even with ADT. Once patients enter into mCRPC, they face with significant declines in quality of life and a dramatically reduced survival period. Thus, doublet therapy, which combines ADT with new hormone therapy (NHT) or ADT with docetaxel chemotherapy, substitutes ADT alone and has become the “gold standard” for the treatment of mHSPC. In recent years, triplet therapy, which combines ADT with NHT and docetaxel chemotherapy, has also achieved impressive effects in mHSPC. This article provides a comprehensive review of the recent applications of the triplet therapy in the field of mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatic NeoplasmsDocetaxelAntineoplastic Combined Chemotherapy ProtocolsHumansMaleProstatic Neoplasms, Castration-ResistantQuality of LifeAntineoplastic Agents, HormonalNeoplasm Metastasis

Stichwörter der Autor:innen

combination therapydoublet therapymetastatic hormone-sensitive prostate cancertriplet therapy

Substanzen

Androgen AntagonistsDocetaxelAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Health Science Center, Ningbo University, Zhejiang, Ningbo 315211, China.
  • Department of General Surgery, Yuyao People's Hospital, Zhejiang, Ningbo 315400, China.
  • Department of Urology, Beilun People's Hospital, Zhejiang, Ningbo 315800, China.
  • Comprehensive Genitourinary Cancer Center, The First Affiliated Hospital of Ningbo University, Zhejiang, Ningbo 315010, China.
  • Translational Research Laboratory for Urology, The First Affiliated Hospital of Ningbo University, Zhejiang, Ningbo 315010, China.
  • Yi-Huan Genitourinary Cancer Group, The First Affiliated Hospital of Ningbo University, Zhejiang, Ningbo 315010, China.

Förderung

  • hejiang Natural Science Fund
  • Ningbo Clinical Research Center for Urological Disease (No

Zitieren

APA

Ye, S. J., Huang, R. D., Fei, X., Tao, Z. L., Liu, W. H., & Ma, Q. (2024). Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgae063

Vancouver

Ye SJ, Huang RD, Fei X, Tao ZL, Liu WH, Ma Q. Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy. Postgraduate Medical Journal. 2024. doi:10.1093/postmj/qgae063

BibTeX
@article{Ye2024,
  author = {Ye, Shi-Jie and Huang, Rui-da and Fei, Xin and Tao, Zhu-Lei and Liu, Wei-Hua and Ma, Qi},
  title = {Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy},
  journal = {Postgraduate Medical Journal},
  year = {2024},
  doi = {10.1093/postmj/qgae063}
}
Kostenlos starten →